OrbusNeich® Medical and P+F Products & Features® came together in November 2020, under a collaborative partnership, to introduce a new portfolio of heart valve products aiming to restore health and extend life

P+F brings to the partnership a series of innovative minimally invasive heart valve products premounted on the delivery system using P+F’s proprietary dry valve technology.  The product portfolio includes the TricValve® Transcatheter Bicaval Valves and the Vienna Aortic Self-Expandable Transcather Valve complemented by transcatheter solutions for pulmonary and mitral valve disease as well as endovascular grafts.  

The growing elderly patient population with the prevalence of moderate-to-severe dysfunctional heart valves is very challenging.  P+F’s unique product line for percutaneous transcatheter-based therapeutics will result in a significant improvement of health-related quality of life for patients, which is an important measure of procedural success in the elderly.

OrbusNeich brings to the partnership vast experience in running a state-of-the-art manufacturing facilities in Shenzhen, China, and will be responsible for distributing the innovative minimally invasive heart valve products to the Asia-Pacific region, including China, Japan, Taiwan, South Korea, Hong Kong, Singapore, Malaysia, Australia and New Zealand.

Over the years, OrbusNeich has brought to market a range of innovative stent and balloon devices, including a series of angioplasty balloon catheters for the management of the most complex lesions, including chronic total occlusion, for both the treatment of coronary and peripheral vascular disease.

The company’s proprietary endothelial progenitor cell (EPC) capture technology has been incorporated onto the COMBO Plus stent for the first true pro healing drug eluting stent. The patented EPC capture technology promotes early vessel healing. We strive for our products to change lives and improve the quality of life for patients. We work closely with our physician partners to understand and meet their needs and those of their patients.

With more than 25 years of experience in the medical field, the leadership team of P+F has built a complete infrastructure for research, development, manufacture, and distribution in order to deliver significant innovations and add value to its customers and patients. P+F is striving to become the “standard of comparison” in the development of state-of-the-art innovative technologies in the field of cardiology products that contribute to human welfare by the application of biomedical engineering in the research, development and manufacture of devices which restore health, extend life and are accessible to all. This powerful partnership supports the OrbusNeich strategic business directive to add important complementary structural heart devices to their coronary and peripheral portfolio and provides P+F with collaboration in offering P+F’s transformational heart valve solutions to patients in Asia-Pacific.